Yousef J

SARS-CoV-2 induces a durable and antigen specific humoral immunity after asymptomatic to mild COVID-19 infection

Havervall S, Jernbom Falk A, Klingström J, ..., Nilsson P, Thålin C

PLoS One 17 (1) e0262169 [2022-01-12; online 2022-01-12]

Category: Biochemistry Category: Health Funder: KAW/SciLifeLab National COVID program Funder: VR Research Area: Biobanks for COVID-19 research Research Area: Drug discovery and repurposing of drugs Research Area: High-throughput and high-content serology Research Area: Host cell systems biology and targets Type: Journal article

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S, Ng H, Jernbom Falk A, ..., Hober S, Thålin C

J Intern Med 291 (1) 72-80 [2022-01-00; online 2021-09-27]

Category: Biochemistry Category: Health Funder: KAW/SciLifeLab National COVID program Research Area: Biobanks for COVID-19 research Research Area: Drug discovery and repurposing of drugs Research Area: High-throughput and high-content serology Research Area: Host cell systems biology and targets Research Area: Viral sequence evolution

Systematic evaluation of SARS-CoV-2 antigens enables a highly specific and sensitive multiplex serological COVID-19 assay.

Hober S, Hellström C, Olofsson J, ..., Hedhammar M, Nilsson P

Clin Transl Immunol 10 (7) e1312 [2021-07-19; online 2021-07-19]

Category: Biochemistry Category: Health Funder: KAW/SciLifeLab National COVID program Research Area: Biobanks for COVID-19 research Research Area: High-throughput and high-content serology Research Area: Host cell systems biology and targets Type: Journal article